Related Experiment Videos
Itraconazole treatment of experimental systemic candidiasis in male rats
Abstract:
After intravenous infection with Candida albicans, rats received daily doses of itraconazole for 3 days. All rats receiving 2.5 mg kg-1 day-1 survived while all rats receiving sham-treatment died. With subsequent reduction of the itraconazole dose to 0.63 mg kg-1 day-1, no survival occurred and mortality rates equalled those of the control group.
Insights
High-dose itraconazole (2.5 mg kg-1 day-1) completely protected rats against intravenous Candida albicans infection. Lower doses (0.63 mg kg-1 day-1) failed to prevent mortality, indicating a dose-dependent survival effect.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- Candida albicans is an opportunistic fungal pathogen causing severe infections.
- Antifungal drug efficacy is crucial for managing invasive candidiasis.
- Itraconazole is a broad-spectrum antifungal agent.
Purpose of the Study:
- To evaluate the efficacy of itraconazole in a rat model of invasive candidiasis.
- To determine the dose-response relationship of itraconazole in treating Candida albicans infection.
Main Methods:
- Rats were intravenously infected with Candida albicans.
- Daily doses of itraconazole (2.5 mg kg-1 day-1 or 0.63 mg kg-1 day-1) were administered for 3 days.
- Survival rates and mortality were compared to a sham-treated control group.
Main Results:
- All rats treated with 2.5 mg kg-1 day-1 itraconazole survived the infection.
- No survival was observed in rats treated with 0.63 mg kg-1 day-1 itraconazole.
- Mortality rates in the lower-dose itraconazole group were comparable to the sham-treated control group.
Conclusions:
- Itraconazole demonstrates significant antifungal activity against Candida albicans in vivo.
- A high dose of itraconazole (2.5 mg kg-1 day-1) is required for complete protection in this model.
- Lower doses of itraconazole are ineffective in preventing mortality from invasive candidiasis.